Community Oncology Pharmacy Association | Strategic Alliance Partners

Judith Alberto, MHA, RPh, BCOP, discusses the COA 2025 Community Oncology Conference, emphasizing its focus on transparency in oncology and the role of data in supporting pharmacists' contributions to patient care.

In 2025, medically integrated dispensing pharmacies face significant challenges, including low reimbursements, restrictive pharmacy benefit manager practices, complex therapies, regulatory barriers such as the Stark delivery law, and the Inflation Reduction Act's financial implications, necessitating urgent advocacy, reform, and collaboration to sustain equitable, patient-centered cancer care.

Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives at Community Oncology Alliance, discusses key policy issues affecting community oncology pharmacists in 2025.

Nick Ferreyros discusses the state and federal regulations impacting payment reform.

Lalan Wilfong, MD, discusses the road to value-based care and payment reform in cancer care.

A session at the Community Oncology Alliance virtual 2021 conference noted that clinical trials have found promising new treatments for patients with breast cancer, offering opportunities for future new approvals and indications.

In patients who received early palliative care, researchers noted a lower percentage of patients with depression, improved quality of life, and, significantly, longer survival.

Panelists at the Community Oncology Alliance (COA) virtual 2021 conference said the impacts of the pandemic on their day-to-day operations were challenging, although they all said they were proud of how their staff handled the rapid changes in spring of 2020.

Staying educated in the formal and informal health care settings surrounding state-of-the-art cancer care in the community practice is essential for success.

As a nonprofit focused on enhancing patient care. COPA is in a unique position to serve as a noncommercial organization dedicated to addressing community oncology pharmacy issues, all in the sole interest of patient care.

The partnership will develop and publish Directions in Oncology PharmacyTM.